Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.38 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL476331 | 0.99 | HTR6 (0.38) | HTR6SLC40A1HTR2CSLC6A4NAMPT | |
| Hydrochloric Acid SCHEMBL3703128 | 0.90 | HTR6 (0.46) | HTR6HTR2CHTR2AKCNH2HTR7 | |
| SCHEMBL3695259 | 0.90 | HTR6 (0.36) | HTR6HTR2CSLC6A4NAMPTHTR2A | |
| Hydrochloric Acid SCHEMBL3695929 | 0.89 | HTR6 (0.36) | HTR6SLC40A1HTR2CSLC6A4NAMPT | |
| SCHEMBL476363 | 0.88 | HTR6 (0.39) | HTR6SLC40A1HTR2CNAMPTKMT2A | |
| SCHEMBL476373 | 0.87 | GLO1 (0.39) | HTR6SLC40A1NAMPT | |
| SCHEMBL476271 | 0.87 | HTR6 (0.40) | HTR6HTR2CSLC6A4HTR2AKCNH2 | |
| Hydrochloric Acid SCHEMBL3690326 | 0.87 | NFE2L2 (0.42) | HTR6SLC40A1HTR2CSLC6A4NAMPT | |
| Hydrochloric Acid SCHEMBL476433 | 0.87 | GLO1 (0.38) | HTR6SLC40A1NAMPT | |
| Hydrochloric Acid SCHEMBL476306 | 0.86 | HTR6 (0.40) | HTR6HTR2CSLC6A4HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412713-B1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-11-30 | — | — | EP | claimed |
| US-8895588-B2 | Pyrazole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-25 | — | — | US | claimed |
| US-20120095057-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | claimed |
| EP-2412713-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-02-01 | — | — | EP | claimed |
| EP-3329921-B1 | TABLET | TAKEDA PHARMACEUTICALS CO (JP) | 2024-03-27 | — | — | EP | disclosed |
| CN-108135915-B | Tablet formulation | 武田药品工业株式会社 | 2021-06-25 | — | — | CN | disclosed |
| US-10835541-B2 | Tablet | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-17 | — | — | US | disclosed |
| US-20180214460-A1 | TABLET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-02 | — | — | US | disclosed |
| EP-3329921-A1 | TABLET | Takeda Pharmaceutical Company Limited (JP) | 2018-06-06 | — | — | EP | disclosed |
| EP-2412713-B1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-8895588-B2 | Pyrazole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895588-B2 | Pyrazole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895588-B2 | Pyrazole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120095057-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095057-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095057-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2412713-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095057-A1 | PYRAZOLE COMPOUND | CEL, HRH2, GIPR | HTR6 2380/4885SLC40A1 2587/4885HTR2C 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.